Medtronic said it will acquire Scientia Vascular in a deal valued at $550 million.
Scientia is a private company operating in Salt Lake City, Utah, with approximately 310 employees. Under founder and current chief technology officer John Lippert, the company has developed access products that enable simplicity and access for physicians treating complex neurovascular conditions. Scientia's portfolio of guidewires and catheters can be integrated with Medtronic's existing suite of neurovascular products.
"Medtronic is thrilled to acquire Scientia to accelerate meaningful innovation in neurovascular care," said Linnea Burman, senior vice president and president of Medtronic's Neurovascular business, which is part of the Neuroscience Portfolio at Medtronic. "This acquisition positions Medtronic with a full suite of products. It builds a strong foundation for Medtronic and supports procedures across both hemorrhagic and acute ischemic stroke. Medtronic's best-in-class therapies, combined with Scientia's leading access portfolio, will be incredibly powerful. With 12 million people globally suffering from stroke each year, we look forward to contributing to better patient outcomes around the world."
"As a company committed to improving patients' lives, we are humbled and excited for what's ahead," said Rick Randall, CEO, Scientia. "Scientia has developed critical technology that has been embraced by physicians. This deal allows us to take our engineering into disease states globally and positions Medtronic with a comprehensive portfolio and complete guidewire line. With the size and scale of Medtronic, the opportunity to treat more patients and drive more impact is truly exciting."
This acquisition is expected to close in the first half of Medtronic's fiscal 2027, subject to regulatory approvals and satisfaction of other closing conditions.
